Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?

被引：0
|
作者：
Perrin, Christophe
Frenel, Jean-Sebastien
Edeline, Julien
Robert, Marie
Tas, Patrick
Lefeuvre-Plesse, Claudia
Gourmelon, Carole
Le Du, Fanny
Campone, Mario
Kerbrat, Pierre
机构：
[1] Ctr Eugene Marquis, Rennes, France
[2] Ctr Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France
[3] Ctr Comprehens Canc, Oncol Med Eugene Marquis, Rennes, France
[4] Inst Canc Ouest, Nantes, France
[5] West Cancerol Insitute Rene Gauducheau, Nantes, France
[6] Inst Canc West ICO, Nantes, France
[7] Med Oncol Eugene Marquis Comprehens Canc Ctr, Rennes, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
550
引用
收藏
页数：1
相关论文
共 15 条
  • [1] FOR WHICH PT1A, BN0M0 HORMONE RESPONSIVE INVASIVE BREAST CARCINOMAS COULD ENDOCRINE THERAPY BE AVOIDED?
    Perrin, C.
    Edeline, J.
    Leseur, J.
    Lavoue, V.
    Tas, P.
    Mesbah, H.
    Lefeuvre-Plesse, C.
    Gedouin, D.
    Penault-Llorca, F.
    Kerbrat, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 105 - 105
  • [2] PT1a,bN0M0 Breast Carcinoma Characteristics and Management: the French ODISSEE Cohort
    Dalenc, F.
    Llorca, F. Penault
    Cohen, M.
    Houvenaeghel, G.
    Piat, J. M.
    Liegeois, P.
    Puyuelo, L.
    Suchaud, J. P.
    Zouai, M.
    Belkacemi, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S379 - S380
  • [3] PT1a,bN0M0 breast carcinoma characteristics and management: The French ODISSEE cohort
    Dalenc, F.
    Penault-Llorca, F. M.
    Cohen, M.
    Houvenaeghel, G.
    Piat, J.
    Liegeois, P.
    Puyuelo, L.
    Suchaud, J.
    Zouai, M. E. H.
    Beauclair, S.
    Belkacemi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Petrelli, Fausto
    Barni, Sandro
    MEDICAL ONCOLOGY, 2011, 28 (02) : 401 - 408
  • [5] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Fausto Petrelli
    Sandro Barni
    Medical Oncology, 2011, 28 : 401 - 408
  • [6] Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis
    F. Petrelli
    S. Barni
    Medical Oncology, 2012, 29 : 2586 - 2593
  • [7] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
    Shinsuke Sasada
    Naoto Kondo
    Hiroya Hashimoto
    Yuko Takahashi
    Kaori Terata
    Kumiko Kida
    Yasuaki Sagara
    Takayuki Ueno
    Keisei Anan
    Akihiko Suto
    Chizuko Kanbayashi
    Mina Takahashi
    Rikiya Nakamura
    Toshiyuki Ishiba
    Michiko Tsuneizumi
    Seiichiro Nishimura
    Yoichi Naito
    Fumikata Hara
    Tadahiko Shien
    Hiroji Iwata
    Breast Cancer Research and Treatment, 2023, 202 : 473 - 483
  • [8] Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
    Sasada, Shinsuke
    Kondo, Naoto
    Hashimoto, Hiroya
    Takahashi, Yuko
    Terata, Kaori
    Kida, Kumiko
    Sagara, Yasuaki
    Ueno, Takayuki
    Anan, Keisei
    Suto, Akihiko
    Kanbayashi, Chizuko
    Takahashi, Mina
    Nakamura, Rikiya
    Ishiba, Toshiyuki
    Tsuneizumi, Michiko
    Nishimura, Seiichiro
    Naito, Yoichi
    Hara, Fumikata
    Shien, Tadahiko
    Iwata, Hiroji
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (03) : 473 - 483
  • [9] Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study
    Sasada, S.
    Takahashi, Y.
    Terata, K.
    Kida, K.
    Sagara, Y.
    Ueno, T.
    Anan, K.
    Suto, A.
    Kanbayashi, C. K.
    Takahashi, M.
    Nakamura, R.
    Ishiba, T.
    Tsuneizumi, M.
    Nishimura, S.
    Naito, Y.
    Hara, F.
    Iwata, H.
    Shien, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S342 - S342
  • [10] Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas
    Rodrigues, M. J.
    Albiges-Sauvin, L.
    Wassermann, J.
    Cottu, P. H.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2530 - 2530
12